Biotech Values

[cjgaddy]

Dew, I know you’re not too fond of my bullish view of Peregrine’s Anti-PS mab, Bavituximab, for the treatment of enveloped viruses (incl. HepC) and solid cancers, but I think it’s fair to offer a differing opinion to yours:

8-10-07 DEWDILIGENCE BIOVALUES #50893:
”Programs on ‘life support’ or unlikely (IMO) to succeed:
• R1626 ( Roche )
• Celgosivir ( Migenix )
• Bavituximab ( PPHM )”

8-7-07 PR: FINAL BAVITUXIMAB PH.1B REPEAT-DOSE RESULTS COMING 11-4-07 IN ORAL PRES. AT AASLD’07
Peregrine’s CEO Steven King:
"We believe that bavituximab represents a unique approach with significant clinical promise for treating chronic hepatitis C virus infections.”
http://tinyurl.com/3cl7n4

I am most interested in following the progress of this recently-initiated 1B trial:

C. PH.1B HCV-HIV CO-INFECT’S MONO REPEAT-DOSE TRIAL:
NIH protocol (init=7-2007): http://clinicaltrials.gov/ct/show/NCT00503347
1 site: St. Michael's MC, Newark (PI Dr. Stephen M Smith)
7-10-07: ENROLLMENT BEGINS for HCV-HIV Co-Infected’s Trial http://tinyurl.com/2g7rdp
...Ascending dose levels of Bavi weekly for up to 8 wks; ~24 patients; designed to assess Safety & PK, but “HCV & HIV viral titers & other biomarkers will be evaluated”.
5-17-07: New Clinical Protocol filed with FDA: http://tinyurl.com/2lpacm

Yes, a long way to go, but I wouldn’t put Bavi on life support just yet!

BEST OF LUCK TO ALL NOVEL ANTI-HCV AGENTS CURRENTLY IN TESTING, WHETHER THEY FALL UNDER THE ANTI-VIRAL OR IMMUNOTHERAPEUTICS CATEGORY.